Upcoming Webinar

JAK inhibitors in dermatology: Unpacking the boxed warning and long-term safety data

THURSDAY, JULY 17, 2025 7PM ET/ 6PM CT/ 4PM PT

The FDA’s approval of JAK inhibitors has transformed the treatment landscape for severe alopecia areata. These medications are also used across a range of autoimmune and inflammatory conditions, including several in dermatology. However, all JAK inhibitors carry a serious safety warning—also known as a box warning—highlighting the risk of significant side effects. 

But what does this warning really mean? In this webinar, board-certified dermatologist and clinical researcher Dr. Jennifer Soung will break down the science behind the FDA’s decision, explore the data that led to the boxed warning, and discuss what long-term safety studies now reveal. She’ll offer practical guidance on how to apply this evolving evidence when considering treatment options for alopecia areata—and help you weigh the risks, benefits, and context for using JAK inhibitors in dermatology today.

Register Here